Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Monopar Therapeutics raised $100 million in a stock offering to fund research and development.

flag Monopar Therapeutics priced a $135 million underwritten offering of common stock and pre-funded warrants, with proceeds expected to net about $100 million after a $35 million stock repurchase from Tactic Pharma. flag The company plans to use funds for research, clinical trials, manufacturing, and working capital. flag The offering, managed by Morgan Stanley, Leerink Partners, and Barclays, is set to close on September 25, 2025, and is part of a shelf registration filed with the SEC. flag The securities are being offered under a prospectus supplement available on the SEC’s website. flag Monopar is developing treatments for Wilson disease and advanced cancers. flag Forward-looking statements involve risks related to regulatory and market factors.

3 Articles